The characteristic changes in human puberty – increased muscle bulk, increased linear growth, and the mineralization of the skeleton – are due, in part, to the combined effects of growth hormone (GH), insulin-like growth factor I (IGF-I), sex hormones and insulin. GH and testosterone, but not oestrogen, are highly protein-anabolic in vivo, and the combined administration of GH and testosterone has synergistic effects on these measures, both in children and adults. GH has no significant effect on enhancing skeletal muscle strength in humans; however, testosterone is highly ergogenic and is largely responsible for the differences in muscle bulk apparent in late puberty between the genders. The results of recent detailed metabolic studies suggest that boys have higher rates of protein synthesis and IGF-I generation than girls, given comparable doses of GH. In patients with a constitutional delay in growth and maturation, relative deficiencies in testosterone and lower IGF-I concentrations are associated with greater rates of total energy expenditure, suggesting that this relatively hormone-insufficient state is associated with a hypermetabolic state. Whether added nutritional supplements, alone or in combination with GH, could improve the growth pattern and final height of these children deserves further study. In conclusion, the metabolic effects of GH and testosterone are complex and they synergize in puberty. These hormones could be of use as protein-anabolic agents in selected catabolic conditions.

Keywords:
Adolescents, Growth hormone, Metabolism, Muscle, Testosterone
1.
Mauras N: GH, sex steroid and IGF-I: metabolic regulation in puberty; in Pescovitz OH, Eugster EA (eds): Pediatric Endocrinology. Baltimore, Lippincott Williams & Wilkins, 2004, pp 299–315.
2.
Horber FF, Haymond MW: Human growth hormone prevents the protein catabolic side effects of prednisone in humans. J Clin Invest 1990;86:265–272.
3.
Mauras N, O’Brien KO, Welch S, Rini A, Helgeson K, Vieira NE, Yergey AL: Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism. J Clin Endocrinol Metab 2000;85:1686–1694.
4.
Mauras N, George D, Evans J, Milov D, Abrams S, Rini A, Welch S, Haymond MW: Growth hormone has anabolic effects in glucocorticosteroid-dependent children with inflammatory bowel disease: a pilot study. Metabolism 2002;51:127–135.
5.
Mauras N, Haymond MW: Are the metabolic effects of GH and IGF-I separable? Growth Horm IGF Res 2005;15:19–27.
6.
Mauras N, Rini A, Welch S, Sager B, Murphy SP: Synergistic effects of testosterone and growth hormone on protein metabolism and body composition in prepubertal boys. Metabolism 2003;52:964–969.
7.
Kuromaru R, Kohno H, Ueyama N, Hassan HM, Honda S, Hara T: Long-term prospective study of body composition and lipid profiles during and after growth hormone (GH) treatment in children with GH deficiency: gender-specific metabolic effects. J Clin Endocrinol Metab 1998;83:3890–3896.
8.
Mauras N, Beaufrere B: Recombinant human insulin-like growth factor I enhances whole body protein anabolism and significantly diminishes the protein catabolic effects of prednisone in humans without a diabetogenic effect. J Clin Endocrinol Metab 1995;80:869–874.
9.
Mauras N: Combined recombinant human growth hormone and recombinant human insulin-like growth factor I: lack of synergy on whole body protein anabolism in normally fed subjects. J Clin Endocrinol Metab 1995;80:2633–2637.
10.
Mauras N, Haymond MW, Darmaun D, Vieira NE, Abrams SA, Yergey AL: Calcium and protein kinetics in prepubertal boys. Positive effects of testosterone. J Clin Invest 1994;93:1014–1019.
11.
Veldhuis JD, Roemmich JN, Richmond EJ, Rogol AD, Lovejoy JC, Sheffield-Moore M, Mauras N, Bowers CY: Endocrine control of body composition in infancy, childhood, and puberty. Endocr Rev 2005;1:114–146.
12.
Mauras N, Hayes V, Welch S, Rini A, Helgeson K, Dokler M, Veldhuis JD, Urban RJ: Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab 1998;83:1886–1892.
13.
Vance ML, Mauras N: Growth hormone therapy in adults and children. N Engl J Med 1999;341:1206–1216.
14.
Neu CM, Rauch F, Rittweger J, Manz F, Schoenau E: Influence of puberty on muscle development at the forearm. Am J Physiol Endocrinol Metab 2002;283:E103–E107.
15.
Bitar A, Vernet J, Coudert J, Vermorel M: Longitudinal changes in body composition, physical capacities and energy expenditure in boys and girls during the onset of puberty. Eur J Nutr 2000;39:157–163.
16.
Schoenau E, Neu CM, Mokov E, Wassmer G, Manz F: Influence of puberty on muscle area and cortical bone area of the forearm in boys and girls. J Clin Endocrinol Metab 2000;85:1095–1098.
17.
Seger JY, Thorstensson A: Muscle strength and electromyogram in boys and girls followed through puberty. Eur J Appl Physiol 2000;81:54–61.
18.
Ramos E, Frontera WR, Llopart A, Feliciano D: Muscle strength and hormonal levels in adolescents: gender related differences. Int J Sports Med 1998;19:526–531.
19.
Duppe H, Cooper C, Gardsell P, Johnell O: The relationship between childhood growth, bone mass, and muscle strength in male and female adolescents. Calcif Tissue Int 1997;60:405–409.
20.
Florini JR, Ewton DZ, Coolican SA: Growth hormone and the insulin-like growth factor system in myogenesis. Endocr Rev 1996;17:481–517.
21.
Yarasheski KE, Campbell JA, Smith K, Rennie MJ, Holloszy JO, Bier DM: Effect of growth hormone and resistance exercise on muscle growth in young men. Am J Physiol 1992;262:E261–E267.
22.
Yarasheski KE, Zachwieja JJ, Campbell JA, Bier DM: Effect of GH and resistance exercise on muscle growth and strength in older men. Am J Physiol 1995;268(2 Pt 1):E268–E276.
23.
Blackman MR, Sorkin JD, Munzer T, Bellantoni MF, Busby-Whitehead J, Stevens TE, Jayme J, O’Connor KG, Christmas C, Tobin JD, Stewart KJ, Cottrell E, St Clair C, Pabst KM, Harman SM: Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 2002;288:2282–2292.
24.
Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R: The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996;335:1–7.
25.
Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, Yarasheski KE, Sinha-Hikim I, Dzekov C, Dzekov J, Magliano L, Storer TW: Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 2005;90:678–688.
26.
Strawford A, Barbieri T, Van Loan M, Parks E, Catlin D, Barton N, Neese R, Christiansen M, King J, Hellerstein MK: Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: a randomized controlled trial. JAMA 1999;281:1282–1290.
27.
Hayes VY, Urban RJ, Jiang J, Marcell TJ, Helgeson K, Mauras N: Recombinant human growth hormone and recombinant human insulin-like growth factor I diminish the catabolic effects of hypogonadism in man: metabolic and molecular effects. J Clin Endocrinol Metab 2001;86:2211–2219.
28.
Rudling M, Norstedt G, Olivecrona H, Reihner E, Gustafsson JA, Angelin B: Importance of GH for the induction of hepatic low density lipoprotein receptors. Proc Natl Acad Sci USA 1992;89:6983–6987.
29.
Oscarsson J, Ottosson M, Vikman-Adolfsson K, Frick F, Enerback S, Lithell H, Eden S: GH but not IGF-I or insulin increases LPL activity in muscle tissues of hypophysectomized rats. J Endocrinol 1999;60:247–255.
30.
Xu XF, DePergola G, Bjorntorp P: Testosterone increases lipolysis and the number of β adrenoreceptors in male rat adipocytes. Endocrinology 1991;128:379–382.
31.
Hossain A, Hornick CA: Androgenic modulation of lipid metabolism at subcellular sites in cholestatic rats. Horm Metab Res 1994;26:19–25.
32.
Yang S, Bjorntorp P, Liu S, Eden S: Growth hormone treatment of hypophysectomized rats increases catecholamine-induced lipolysis and the number of beta-adrenergic receptors in adipocytes: no differences in the effects of growth hormone on different fat depots. Obes Res 1996;4:471–478.
33.
Mauras N, Rini A, Welch S, Sager B, Murphy SP: Synergistic effects of testosterone and growth hormone on protein metabolism and body composition in prepubertal boys. Metabolism 2003;52:964–969.
34.
Bottner A, Kratzsch J, Muller G, Kapellen TM, Bluher S, Keller E, Bluher M, Kiess W: Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab 2004;89:4053–4061.
35.
Amiel SA, Caprio S, Sherwin RS, Plewe G, Haymond MW, Tamborlane WV: Insulin resistance of puberty: a defect restricted to peripheral glucose metabolism. J Clin Endocrinol Metab 1991;72:277–282.
36.
Arslanian SA, Kalhan SC: Correlations between fatty acid and glucose metabolism. Potential explanation of insulin resistance of puberty. Diabetes 1994;43:908–914.
37.
Mauras N: Estrogens do not affect whole-body protein metabolism in the prepubertal female. J Clin Endocrinol Metab 1995;80:2842–2845.
38.
Mauras N, O’Brien KO, Klein KO, Hayes V: Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab 2000;85:2370–2377.
39.
Burman P, Johansson AG, Siegbahn A, Vessby B, Karlsson FA: Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 1997;82:550–555.
40.
Cohen P, Bright GM, Rogol AD, Kappelgaard AM, Rosenfeld RG: Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: implications for efficacy and safety. J Clin Endocrinol Metab 2002;87:90–98.
41.
Han JC, Balagopal P, Sweeten S, Darmaun D, Mauras N: Evidence for hypermetabolism in boys with constitutional delay of growth and maturation. J Clin Endocrinol Metab 2006;91:2081–2086.
© 2006 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.